Open science drug discovery partnership, READDI, aims to invest $125 million to prevent future pandemics
April 14, 2020
The Structural Genomics Consortium (SGC), the University of North Carolina at Chapel Hill and the Eshelman Institute for Innovation have announced the launch of the Rapidly Emerging Antiviral Drug Development Initiative (READDI), a global organization aimed at discovering and developing drugs to put “on the shelf” for clinical trial testing in anticipation of future viral pandemics.
“The COVID-19 pandemic highlights the need for the world’s top researchers and drug discoverers to work together to invent new therapies,” said SGC Chief Executive Officer Aled Edwards. “We should have done this decades ago, but READDI has the potential to make sure we are never caught off-guard again.”
READDI is modeled after DNDi, a proven model for nonprofit drug research and development. In READDI, projects will adopt extreme open science methods — sharing drug discovery progress in real time, so that all can benefit.
“We are excited to support this much needed effort in antiviral drug development,” said DNDi Research and Development Director Laurent Fraisse. “We are happy to lend our hand in any way to ensure the global community is better prepared for any future pandemics.”
“We are proud to help launch READDI. We are also proud of the three schools — the Eshelman School of Pharmacy, the School of Medicine and the Gillings School of Global Public Health — that created this concept and will be collaborating closely. It is uniquely structured to innovate for the public good, just as we do at Carolina,” said UNC-Chapel Hill Chancellor Kevin M. Guskiewicz. “Through this initiative, researchers will be able to create new therapies that will help people live longer, healthier lives.”
To learn more, visit READDI.org or contact the EII Director at johnbamforth@readdi.org.
Contact the Gillings School of Global Public Health communications team at sphcomm@unc.edu.
